Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EBS 
Emergent Biosolutions Inc (EBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: EBS (1-star) is a SELL. SELL since 5 days. Simulated Profits (-13.99%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.46% | Avg. Invested days 37 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 434.28M USD | Price to earnings Ratio 3.11 | 1Y Target Price 13.5 |
Price to earnings Ratio 3.11 | 1Y Target Price 13.5 | ||
Volume (30-day avg) 3 | Beta 2.04 | 52 Weeks Range 4.02 - 12.73 | Updated Date 09/14/2025 |
52 Weeks Range 4.02 - 12.73 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.38% | Operating Margin (TTM) 0.35% |
Management Effectiveness
Return on Assets (TTM) 5.03% | Return on Equity (TTM) 30.24% |
Valuation
Trailing PE 3.11 | Forward PE 2.06 | Enterprise Value 834777945 | Price to Sales(TTM) 0.51 |
Enterprise Value 834777945 | Price to Sales(TTM) 0.51 | ||
Enterprise Value to Revenue 1.03 | Enterprise Value to EBITDA 2.42 | Shares Outstanding 53351100 | Shares Floating 51872740 |
Shares Outstanding 53351100 | Shares Floating 51872740 | ||
Percent Insiders 2.84 | Percent Institutions 70.19 |
Upturn AI SWOT
Emergent Biosolutions Inc
Company Overview
History and Background
Emergent BioSolutions Inc. was founded in 1998 as BioPort Corporation to acquire and modernize the Michigan Biologic Products Institute, the sole supplier of anthrax vaccine to the U.S. Department of Defense. Over time, it has expanded through acquisitions and strategic partnerships to become a global specialty biopharmaceutical company.
Core Business Areas
- Anthrax Vaccines: Production and sale of BioThrax and AV7909 (Cyfendus) anthrax vaccines for government stockpiles and civilian use.
- Narcan Nasal Spray: Sales of Narcan Nasal Spray, an opioid overdose reversal medication, has greatly enhanced the company revenue in 2023-2024
- Medical Countermeasures: Development and manufacturing of medical countermeasures against chemical, biological, radiological, nuclear threats, and emerging infectious diseases.
- Contract Development and Manufacturing (CDMO): Provides development and manufacturing services for pharmaceutical and biotechnology companies.
Leadership and Structure
Emergent BioSolutions is led by a Chief Executive Officer (CEO) and has a structured executive team overseeing various departments such as R&D, manufacturing, finance, and commercial operations. The organizational structure includes business units focused on specific product lines and service offerings.
Top Products and Market Share
Key Offerings
- BioThrax/AV7909 (Cyfendus): Anthrax vaccines used for pre- and post-exposure prophylaxis. Competitors include private companies with anthrax vaccines in earlier stages of development. Market share data is difficult to ascertain precisely, but Emergent holds a dominant position in the U.S. government market.
- Narcan Nasal Spray: An opioid antagonist used to treat known or suspected opioid overdose. Emergent purchased this product line in 2023, and it is one of the more highly visible brand-name products in their product portfolio. Competitors include Teva Pharmaceuticals' generic naloxone nasal spray and Amphastar Pharmaceuticals' injectable naloxone. Market Share data for Narcan is about 70% with the remainder shared by Teva and Amphastar.
Market Dynamics
Industry Overview
The biodefense and medical countermeasures industry is driven by government funding and public health concerns related to bioterrorism and emerging infectious diseases. The CDMO market is growing due to increasing outsourcing by pharmaceutical and biotech companies.
Positioning
Emergent BioSolutions is a key player in the biodefense market, particularly for anthrax vaccines. They also occupy a niche position in the opioid overdose reversal market with Narcan. Their CDMO services add diversification.
Total Addressable Market (TAM)
The biodefense market is estimated to be in the billions of dollars annually. The opioid overdose reversal market is also significant, driven by the ongoing opioid crisis. The CDMO market is in the hundreds of billions globally. Emergent captures a portion of each of these markets.
Upturn SWOT Analysis
Strengths
- Established relationship with the U.S. government for anthrax vaccines
- Proprietary technologies and manufacturing capabilities
- Experienced management team
- Diversified revenue streams through CDMO services and Narcan
Weaknesses
- Reliance on government contracts, subject to political and budgetary changes
- Past manufacturing quality control issues
- High debt levels
- Volatility in stock price due to market perception of quality control issues.
Opportunities
- Expanding CDMO services to new clients and therapeutic areas
- Developing new medical countermeasures for emerging threats
- Acquiring additional products or companies to diversify portfolio
- Increased Narcan sales due to increased opioid crisis and access.
Threats
- Competition from other biodefense companies
- Loss of government contracts
- Regulatory changes impacting product approvals and manufacturing standards
- Generic competition for Narcan
Competitors and Market Share
Key Competitors
- SRAX
- HALB
- PRTK
Competitive Landscape
Emergent BioSolutions' advantages include its established relationship with the U.S. government and its proprietary technologies. Disadvantages include reliance on government contracts and competition from other biodefense companies. Increased competition with other pharmaceutical companies with Narcan.
Major Acquisitions
Adapt Pharma
- Year: 2018
- Acquisition Price (USD millions): 735
- Strategic Rationale: Acquired Narcan (naloxone HCl) nasal spray, a life-saving treatment for opioid overdose, to expand its portfolio of products addressing public health threats.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by government contracts, acquisitions, and expansion of CDMO services.
Future Projections: Analyst projections vary, depending on government funding levels, success of new product development, and CDMO performance.
Recent Initiatives: Recent initiatives include expanding CDMO capacity, launching new products, and securing government contracts.
Summary
Emergent BioSolutions holds a strong position in the biodefense market, particularly with its anthrax vaccines. The recent acquisition of Narcan has the potential to offset past product failures and improve future revenues. Reliance on government contracts and quality control concerns are ongoing risks that need to be managed effectively. Their CDMO business also diversifies the company and makes them less subject to government actions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data and TAM are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Emergent Biosolutions Inc
Exchange NYSE | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2006-11-15 | CEO, President & Director Mr. Joseph C. Papa Jr., M.B.A., R.Ph. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 900 | |
Full time employees 900 | |||
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.